Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 4/20 | 0.34 |
| ▸ | AXL | P30530 | 4/20 | 0.34 |
| ▸ | ICMT | O60725 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607183 | 0.91 | GRM4 (0.40) | CNR1HRH2GRM4CNR2KDM4E | |
| SCHEMBL2666213 | 0.86 | CNR1 (0.41) | CNR1HRH2GRM4MAP3K5CNR2 | |
| SCHEMBL1606614 | 0.85 | CNR1 (0.40) | CNR1HRH2MAP3K5CNR2RAB9A | |
| SCHEMBL1608157 | 0.84 | CNR1 (0.40) | CNR1HRH2GRM4MAP3K5CNR2 | |
| SCHEMBL1606911 | 0.84 | CNR1 (0.39) | CNR1HRH2MAP3K5CNR2MET | |
| SCHEMBL13134884 | 0.84 | CNR1 (0.39) | CNR1HRH2GRM4MAP3K5CNR2 | |
| SCHEMBL9072122 | 0.83 | CNR1 (0.44) | CNR1HRH2MAP3K5CNR2MET | |
| SCHEMBL1606778 | 0.83 | CNR1 (0.44) | CNR1HRH2MAP3K5CNR2NPC1 | |
| SCHEMBL10269410 | 0.83 | CNR1 (0.38) | CNR1HRH2MAP3K5CNR2PIK3C3 | |
| SCHEMBL1608169 | 0.80 | CNR1 (0.41) | CNR1HRH2MAP3K5CNR2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | CNR1 616/4885HRH2 736/4885GRM4 3316/4885 |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | GCKR, GCK, GALK1 | CNR1 568/4885HRH2 2569/4885GRM4 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.